These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29700208)

  • 1. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile.
    Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X
    Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].
    Liang Y; Hou H; Jiang M; Zhang C; Liu D; Zhang X
    Zhongguo Fei Ai Za Zhi; 2020 Apr; 23(4):239-246. PubMed ID: 32316711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.
    Hou H; Zhang C; Qi X; Zhou L; Liu D; Lv H; Li T; Sun D; Zhang X
    Cancer Biol Ther; 2020; 21(1):26-33. PubMed ID: 31594446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique profiles of targetable genomic alterations and prognosis in young Chinese patients with lung adenocarcinoma.
    Chen L; Hu X; Wu H; Liu J; Mu X; Wu H; Zhao Y
    Pathol Res Pract; 2019 Jun; 215(6):152407. PubMed ID: 30962004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
    Vavalà T; Monica V; Lo Iacono M; Mele T; Busso S; Righi L; Papotti M; Scagliotti GV; Novello S
    Lung Cancer; 2017 May; 107():84-90. PubMed ID: 27346245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
    Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E; Lade-Keller J; Stougaard M
    Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
    Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing.
    Park E; Shim HS
    Cancer Res Treat; 2020 Apr; 52(2):543-551. PubMed ID: 31726498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.
    Yang SR; Lin CY; Stehr H; Long SR; Kong CS; Berry GJ; Zehnder JL; Kunder CA
    J Mol Diagn; 2018 Mar; 20(2):184-194. PubMed ID: 29269277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.